HDA UK MEDIA AND POLITICAL BULLETIN – 19 July 2017

MEDIA SUMMARY 

SecurMed signs letter of intent with Arvato
SecurMed, 19 July 2017

SecurMed, the UK’s verification organization, has signed a letter of intent with its German tech firm Arvato Systems GmbH. Arvato will be responsible for implementing an IT Blueprint Service across SecurMed’s information systems. SecurMed manages the medicines verification system under the MHRA and the Department of Health. SecurMed has also been embedded with the major drug supply chain within the UK. Arvato employs 3000 people in 25 locations and provides end to end IT solutions and its own serialization service.

Cyber attacks top digital risk for life science companies
European Pharmaceutical Journal, Steve Bremer, 18 July 2017

The Law firm Gowling WLG has identified cyber security as the most pressing challenge facing the pharmaceutical and life sciences industry. The risk was identified as highest for firms between 250 and 350 people. The Digital Risk Calculator used to measure the scale of the threat also noted that British firms identified 2-25% fewer cyber threats than their French and German counterparts. External cyber threats were considered the most pressing concern, with 51% of respondents saying that the level of external threat was likely to increase over the next three years. Only 16% of British respondents believed they were prepared for cyber risks, and only 30% had utilized legal help in setting up cyber protection systems.

PARLIAMENTARY COVERAGE

Lord Lester of Herne Hill
Asked on: 10 July 2017 Department of Health Lords HL625 Her Majesty’s Government what is their assessment of the benefits and costs to the UK of membership of the European Medicines Agency.

Lord O’Shaughnessy
Answered on: 18 July 2017
We recognise the important role that the European Medicines Agency plays in the protection of human and animal health.

In the negotiations, the Government will discuss with the European Union and Member States how best to continue cooperation in the field of medicines regulation in the best interests of both the United Kingdom and the EU. As my Rt. hon. Friends the Secretaries of State for Health and Business said in their 4 July letter in the Financial Times, the UK is fully committed to continuing the close working relationship with our European partners. Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and sharing of data.

I underlined this message, in particular the value the UK places on ongoing co-operation, at the BioIndustry Association and Medicines and Healthcare products Regulatory Agency conference on 14 July.

FULL COVERAGE 

SecurMed signs letter of intent with Arvato
SecurMed, 19 July 2017

FOR INFORMATION:
SecurMed UK, the UK Medicines Verification Organisation is entering into a Letter of Intent with Arvato Systems GmbH as the IT Blueprint Service Provider for the United Kingdom.

Following a robust and competitive selection process SecurMed UK, the UK Medicines Verification Organisation is pleased to announce its intention to enter into a Letter of Intent with Arvato Systems GmbH as the IT Blueprint Service Provider for the United Kingdom. The UK is one of the largest and most complex markets for medicines supply within Europe and the appointment of Arvato Systems represents a significant milestone in the UK’s journey to meet its obligations under the Falsified Medicines Directive and associated Delegated Regulation. SecurMed UK and Arvato Systems look forward to working together to enable the UK medicines supply and healthcare sectors to successfully implement the UK Medicines Verification System by 9 February 2019.

About SecurMed UK
SecurMed UK is the not-for profit organization which will manage the UK Medicines Verification System under the supervision of the UK national competent authorities – MHRA and Department of Health. SecurMed UK has been incorporated by the principal supply chain stakeholder associations (Association of British Pharmaceutical Industry (ABPI), British Generic Manufacturers Association (BGMA), British Association of European Pharmaceutical Distributors (BAEPD), Healthcare Distribution Association (HDA), National Pharmacy Association (NPA) and Company Chemists’ Association (CCA)) as required by the Falsified Medicines Directive.

About Arvato Systems
Global IT specialist Arvato Systems supports major companies through digital transformation. More than 3,000 staff in over 25 locations epitomize in-depth technology expertise, industry knowledge and focus on customer requirements. Working as a team, we develop innovative IT solutions, transition our clients into the Cloud, integrate digital processes and take on IT systems operation and support.
In Healthcare, Arvato Systems provides its own serialization solutions covering the entire end-to-end process chain. These solutions support both individual producers and national verification systems. Arvato Systems was chosen as an official service provider by the European Medicines Verification Organization (EMVO). We rely on a dedicated team of serialization experts that has already carried out numerous international projects.

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?